Correlation Between Tempest Therapeutics and Monopar Therapeutics
Can any of the company-specific risk be diversified away by investing in both Tempest Therapeutics and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tempest Therapeutics and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tempest Therapeutics and Monopar Therapeutics, you can compare the effects of market volatilities on Tempest Therapeutics and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tempest Therapeutics with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tempest Therapeutics and Monopar Therapeutics.
Diversification Opportunities for Tempest Therapeutics and Monopar Therapeutics
-0.77 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Tempest and Monopar is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding Tempest Therapeutics and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Tempest Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tempest Therapeutics are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Tempest Therapeutics i.e., Tempest Therapeutics and Monopar Therapeutics go up and down completely randomly.
Pair Corralation between Tempest Therapeutics and Monopar Therapeutics
Given the investment horizon of 90 days Tempest Therapeutics is expected to under-perform the Monopar Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Tempest Therapeutics is 1.18 times less risky than Monopar Therapeutics. The stock trades about -0.12 of its potential returns per unit of risk. The Monopar Therapeutics is currently generating about 0.22 of returns per unit of risk over similar time horizon. If you would invest 1,621 in Monopar Therapeutics on August 30, 2024 and sell it today you would earn a total of 449.00 from holding Monopar Therapeutics or generate 27.7% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Tempest Therapeutics vs. Monopar Therapeutics
Performance |
| Timeline |
| Tempest Therapeutics |
| Monopar Therapeutics |
Tempest Therapeutics and Monopar Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Tempest Therapeutics and Monopar Therapeutics
The main advantage of trading using opposite Tempest Therapeutics and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tempest Therapeutics position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.| Tempest Therapeutics vs. Indaptus Therapeutics | Tempest Therapeutics vs. Rezolute | Tempest Therapeutics vs. Forte Biosciences | Tempest Therapeutics vs. Sana Biotechnology |
| Monopar Therapeutics vs. Anebulo Pharmaceuticals | Monopar Therapeutics vs. Acrivon Therapeutics, Common | Monopar Therapeutics vs. Pmv Pharmaceuticals | Monopar Therapeutics vs. Molecular Partners AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |